AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04704999
Drug: Artemether 20 mg-Lumefantrine 120 mg
RxNorm normalized name: artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
Trial: NCT06346262
Drug: Valtoco Nasal Product
RxNorm normalized name: Valtoco Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
Trial: NCT05402332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo equivalent
Trial: NCT05800665
Drug: RO7656594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7656594 will be administered orally at specified dose on specified days.
Trial: NCT05547750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar-looking placebo tablets
Trial: NCT05868525
Drug: Aspirin 325Mg Tab, Aspirin 81Mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
Trial: NCT04956432
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 Dose 1 ,tablets, QD
Trial: NCT06550141
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alkylating agent
Trial: NCT05821517
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
Trial: NCT06364696
Drug: ASP4396
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT04456517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine-matched placebo tablet
Trial: NCT04992962
Drug: CBD/CBN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
Trial: NCT04992962
Drug: CBD/THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
Trial: NCT04992962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive compound.
Trial: NCT06308913
Drug: INCB081776
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
Trial: NCT06343792
Drug: RLS-0071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
Trial: NCT05437250
Drug: Non interventional study
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
Trial: NCT05681572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
Trial: NCT06235749
Drug: Calcium Gluconate 10%
RxNorm normalized name: Calcium Gluconate 10% Solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Calcium Gluconate 10% IV following umbilical cord clamping
Trial: NCT05974345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
Trial: NCT06188702
Drug: S095035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S095035 will be taken orally once daily in 28-day cycle.
Trial: NCT04754945
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT06338826
Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir
Trial: NCT04734197
Drug: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination of a topical immunosuppressant and a topical corticosteroid solution
Trial: NCT04734197
Drug: Mycophenolic Acid 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical immunosuppressant
Trial: NCT04734197
Drug: Mycophenolic Acid 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical immunosuppressant
Trial: NCT04734197
Drug: Placebo Comparator: Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical vehicle solution
Trial: NCT06075745
Drug: CMV-MVA Triplex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
Trial: NCT05377333
Drug: LY3457263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05377333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT06520540
Drug: HDM1002 100 mg QD 12weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
Trial: NCT06520540
Drug: HDM1002 200 mg QD 12weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
Trial: NCT06520540
Drug: HDM1002 400 mg QD 12weeks，Q 2W for titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
Trial: NCT06520540
Drug: HDM1002 400 mg QD 12weeks，Q 3W for titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
Trial: NCT04146298
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered prior to cell infusion.
Trial: NCT04767308
Drug: Cyclophosphamide, fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
Trial: NCT06367218
Drug: opioid-free strategy
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine was used for induction and maintenance of anesthesia
Trial: NCT06093841
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT04383119
Drug: No Intervention: Observational Cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according clinical practice
Trial: NCT06073119
Drug: SAR441566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06073119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06260527
Drug: ARTS-011
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
Trial: NCT06260527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
Trial: NCT05872477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
Trial: NCT05532046
Drug: BAY2413555 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY2413555 Dose 1
Trial: NCT05532046
Drug: BAY2413555 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY2413555 Dose 2
Trial: NCT05532046
Drug: Placebo to BAY2413555
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to BAY2413555
Trial: NCT05660421
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth or by vein
Trial: NCT06310785
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
Trial: NCT06039020
Drug: Anti-human thymocyte immunoglobulin, equine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
Trial: NCT05166343
Drug: Epinephrine Injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
Trial: NCT06503094
Drug: CD19&CD20 bispecific CAR-T cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
Trial: NCT05904626
Drug: ELGN-2112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
Trial: NCT05904626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
Trial: NCT04177004
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04774003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
Trial: NCT05346835
Drug: Cilta-cel OOS Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
Trial: NCT05857163
Drug: Clarithromycin placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID, taken orally within half an hour after breakfast and dinner.
Trial: NCT05857163
Drug: Clarithromycin tablets
RxNorm normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg, BID, taken orally within half an hour after breakfast and dinner.
Trial: NCT05571878
Drug: Saline nasal spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
Trial: NCT06499090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
Trial: NCT05418868
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuPH20 will be administered.
Trial: NCT06517797
Drug: S1B-509
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S1B-509 has multiple neurotransmitter activities
Trial: NCT05998928
Drug: Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0
Trial: NCT05074602
Drug: SHR8008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
Trial: NCT06127225
Drug: Proliverenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
Trial: NCT06127225
Drug: Placebo caplets of Proliverenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 caplets of Proliverenol Placebo daily
Trial: NCT05676489
Drug: [F-18]MeFAMP PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
Trial: NCT05636514
Drug: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
RxNorm normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
Trial: NCT04971395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 or 4 mg/kg
Trial: NCT06106945
Drug: AZD0305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0305
Trial: NCT06460948
Drug: Norethindrone Acetate-Ethinyl Estradiol
RxNorm normalized name: norethindrone acetate-ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
Trial: NCT04968210
Drug: Hyperpolarized 13C-pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of hyperpolarized 13C-pyruvate to assess metabolic remodeling in PAH
Trial: NCT05692180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered SC to the patients.
Trial: NCT06045247
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06453083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be dispensed to the participants for 6-days.
Trial: NCT06330077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment administration
Trial: NCT05041647
Drug: 25:1 CBD/THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 dose (1 mL) of HIGH CBD~* 50 mg/ml CBD and 2 mg/ ml THC
Trial: NCT05041647
Drug: 5:1 CBD/THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 dose (1 mL) of LOW CBD~* 10 mg/ml CBD and 2 mg/ ml THC
Trial: NCT04831684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be getting placebo for 8 days of dosing.
Trial: NCT04936841
Drug: NKTR-214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
Trial: NCT04936841
Drug: anti-PD-1 therapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunotherapy drug, monoclonal antibody
Trial: NCT06295328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
Trial: NCT04998487
Drug: LY3471851
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05043376
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard COVID-19 care as per the hospital guidelines
Trial: NCT06680089
Drug: [18F]RCCB6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
Trial: NCT05218499
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin
Trial: NCT06236295
Drug: SHR6508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR6508 will be administered to all the eligible subjects
Trial: NCT05567601
Drug: DOXIL/CAELYX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
Trial: NCT06096038
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 300 mg/meter square IV
Trial: NCT05595642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC placebo Q2W
Trial: NCT03954327
Drug: Placebo Oral Capsule [CEBOCAP]
RxNorm normalized name: Placebo Oral Capsule [CEBOCAP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
Trial: NCT05795517
Drug: HSK31679 medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
Trial: NCT00997542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05795517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo ，QD，oral，Day1 to week 12
Trial: NCT06323174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Trial: NCT05419479
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every two weeks through an infusion at a dose determined by physician
Trial: NCT06130449
Drug: Natesto testosterone intranasal gel
RxNorm normalized name: testosterone Nasal Gel [Natesto]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
Trial: NCT06130449
Drug: Ayr Saline Nasal Gel
RxNorm normalized name: Ayr Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of Ayr (one spray per nostril) will be administered to each participant.
Trial: NCT05200104
Drug: PXL065
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXL065 22.5 mg QD
Trial: NCT05024305
Drug: TWP-102 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05049980
Drug: Medical treatment with Mifégyne® and MisoOne®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
Trial: NCT04974359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - capsules
Trial: NCT05243654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + standard-of-care MDT
Trial: NCT05998642
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.5mg/m2 IV
Trial: NCT06545526
Drug: celecoxib monotherapy
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.